CO2019011271A2 - Análogos de deutetrabenazina, su preparación y uso - Google Patents

Análogos de deutetrabenazina, su preparación y uso

Info

Publication number
CO2019011271A2
CO2019011271A2 CONC2019/0011271A CO2019011271A CO2019011271A2 CO 2019011271 A2 CO2019011271 A2 CO 2019011271A2 CO 2019011271 A CO2019011271 A CO 2019011271A CO 2019011271 A2 CO2019011271 A2 CO 2019011271A2
Authority
CO
Colombia
Prior art keywords
deutetrabenazine
analogs
preparation
compositions
same
Prior art date
Application number
CONC2019/0011271A
Other languages
English (en)
Spanish (es)
Inventor
Chengzi Zhang
Jim Kerr
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of CO2019011271A2 publication Critical patent/CO2019011271A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
CONC2019/0011271A 2017-03-15 2019-10-10 Análogos de deutetrabenazina, su preparación y uso CO2019011271A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
CO2019011271A2 true CO2019011271A2 (es) 2020-02-28

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011271A CO2019011271A2 (es) 2017-03-15 2019-10-10 Análogos de deutetrabenazina, su preparación y uso

Country Status (20)

Country Link
US (4) US11813232B2 (https=)
EP (1) EP3596077A1 (https=)
JP (3) JP7608050B2 (https=)
KR (2) KR20230003308A (https=)
CN (1) CN110709398A (https=)
AR (1) AR111182A1 (https=)
AU (2) AU2018236336B2 (https=)
BR (1) BR112019018966A2 (https=)
CA (1) CA3056612A1 (https=)
CL (1) CL2019002629A1 (https=)
CO (1) CO2019011271A2 (https=)
EA (1) EA201992168A1 (https=)
IL (1) IL269132A (https=)
MX (1) MX2019010913A (https=)
PE (1) PE20191819A1 (https=)
SG (1) SG11201908477QA (https=)
TW (1) TWI772382B (https=)
UA (1) UA127052C2 (https=)
WO (1) WO2018170214A1 (https=)
ZA (1) ZA201906326B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування
TWI784220B (zh) 2018-12-13 2022-11-21 美商奧斯拜客斯製藥有限公司 腦性麻痺運動障礙之治療方法
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US11311488B2 (en) * 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EA201791466A1 (ru) * 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування

Also Published As

Publication number Publication date
EA201992168A1 (ru) 2020-03-16
JP7631572B2 (ja) 2025-02-18
AU2018236336B2 (en) 2022-02-24
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
JP2023010754A (ja) 2023-01-20
BR112019018966A2 (pt) 2020-04-22
US20220040170A1 (en) 2022-02-10
MX2019010913A (es) 2020-01-20
TW201840317A (zh) 2018-11-16
EP3596077A1 (en) 2020-01-22
AU2022203369A1 (en) 2022-06-09
AU2022203369B2 (en) 2024-04-04
PE20191819A1 (es) 2019-12-27
WO2018170214A1 (en) 2018-09-20
US20200016148A1 (en) 2020-01-16
UA127052C2 (uk) 2023-03-29
US20220088006A1 (en) 2022-03-24
CA3056612A1 (en) 2018-09-20
CN110709398A (zh) 2020-01-17
KR20200003791A (ko) 2020-01-10
US11813232B2 (en) 2023-11-14
JP2020510073A (ja) 2020-04-02
IL269132A (en) 2019-11-28
US11179386B2 (en) 2021-11-23
TWI772382B (zh) 2022-08-01
JP7608050B2 (ja) 2025-01-06
KR20230003308A (ko) 2023-01-05
NZ757789A (en) 2024-08-30
JP2024050724A (ja) 2024-04-10
AR111182A1 (es) 2019-06-12
US20180263972A1 (en) 2018-09-20
US12502385B2 (en) 2025-12-23
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CO2019011271A2 (es) Análogos de deutetrabenazina, su preparación y uso
CO2019012957A2 (es) Inhibidores de quinasa y usos de los mismos
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CR20160419A (es) Nuevos compuestos biciclicos
DOP2017000298A (es) Reguladores de nrf2
NI201400125A (es) Antagonistas de st2l y métodos de uso
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
UY37410A (es) Antagonistas de trpv4
MX2021006977A (es) Anellosomas y metodos de uso.
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX2017000862A (es) Formulacion de factor viii.
MX2016003215A (es) Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales